ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2013

Abstract Number: 352

Efficacy and Safety Of Vaccination Against seasonal 2012 Influenza Virus Among Patients With Psoriatic Arthritis and Psoriasis

Arik Polackek1, Yuri Korobko1, Noa Madar-Balakirski1, Uri Arad2, David Levartovsky3, Ilana Kaufman4, Marina Anouk5, Irena Litinsky6, Ella Mendelson7, Daphna Paran8, Hagit Matz9, Dan Caspi10, Michal Mandelbaum11 and Ori Elkayam12, 1Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel, 2Department of Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 3Rheumatology, Tel Aviv Medical Ctr, Tel Aviv, Israel, 4Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-aviv, Israel, 5Rheumatology, Tel Aviv Sourasky Medical Ctr, Tel-Aviv University, Tel Aviv, Israel, 6Department of Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine Tel Aviv University, Tel Aviv, Israel, 7Central Virology Laboratory, Sheba Medical Center, Ramat Gan, Israel, 8Rheumatology, Tel Aviv Sourasky Medical Ctr, Tel-Aviv university, Tel Aviv, Israel, 9Dermatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 10Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 11Central Virology Department, Sheba Medical Center, Tel Aviv, Israel, 12Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel- Aviv, Israel

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2013

Keywords: Psoriatic arthritis and vaccines

Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Psoriatic Arthritis: Clinical Aspects and Treatment I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Patients with psoriatic arthritis (PsA) and psoriasis (Pso) are considered to be immunosuppressed and are therefore recommended to receive vaccination against seasonal influenza. However, in this population of patients, data on the efficacy and safety of vaccination against influenza is scarce.The purpose of this study was to assess the efficacy and safety of vaccination against seasonal influenza in psoriatic arthritis and psoriasis patients.

Methods: Patients with PsA, Pso and healthy controls were vaccinated using the Sanofi Pasteur vaccine recommended by the WHO in 2012 which included 3 serotypes (A/California/7/2009, A/Victoria/361/2011 and aB/Wisconsin/1/2010 influenza virus i.eH1N1, H2N3 and B). Clinical and laboratory assessment were performed on the day of the vaccination and 4-6 weeks later. The immunogenicity of the vaccine was evaluated by hemagglutination inhibition assay. Geometric mean titers and the rate of seroconversion was analyzed in each group. The effect of the vaccine on disease activity  was evaluated using 68 tender and 66 joint counts, number of  dactylitis, psoriasis area severity index (PASI), patient visual analogue scale (VAS) for pain, physician VAS for pain, c-reactive protein (CRP) and erythrocyte sedimentation rate (ESR).     

Results:

67 patients (63 PsA, 4 Pso, mean age 50.1, 37 female, 30 male, 55.2% treated with TNF α blockers, 31.3% on disease-modifying anti rheumatic drugs (DMARDs) ) and 30 healthy controls participated in this study. Immunogenicity: The geometric mean titers increased significantly in both the patients and control group for each of the subtypes tested. A substantial and similar proportion of patients in both groups responded to the vaccine. The response rate was not affected by parameters such as age, gender, disease activity or the use of TNF α blockers or DMARDs. Effect of the vaccine on parameters of disease activity: no significant changes were observed in the tender and swollen joint counts, dactylitis, PASI, global evaluation of the patient and physician and ESR, while a raise in CRP was noticed. The most common side effect was transient local inflammation at the site of vaccination, the rate being similar in both groups.

Conclusion:

Vaccination against seasonal influenza is safe and induces an appropriate response in patients with psoriatic arthritis and psoriasis, similar to healthy controls.


Disclosure:

A. Polackek,
None;

Y. Korobko,
None;

N. Madar-Balakirski,
None;

U. Arad,
None;

D. Levartovsky,
None;

I. Kaufman,
None;

M. Anouk,
None;

I. Litinsky,
None;

E. Mendelson,
None;

D. Paran,
None;

H. Matz,
None;

D. Caspi,
None;

M. Mandelbaum,
None;

O. Elkayam,
None.

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-safety-of-vaccination-against-seasonal-2012-influenza-virus-among-patients-with-psoriatic-arthritis-and-psoriasis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology